Thromboembolic Complications of Cancer and Management

Venöz tromboemboiizm kanser hastalarında mortaiite ve morbiditenin önemli bir nedenidir. İmmobiHzasyon, cerrahi girişimler, hormona! tedaviler, kemoterapi ve venöz kateter kullanımı ile meydana gelen vasküler hasarlar venöz tromboemboiizm için risk faktörleridir. Bunun yanı sıra birçok kanser hücresi koagüiasyon sistemini doğrudan ya da dolaylı olarak aktive etme özelliği olan prokoagüian maddeler salgılar. Kanser hastalarında uzun süreli yatış, cerrahi girişim gibi venöz tromboemboiizm oluşumu için yüksek riskli durumlarda düşük molekül ağırlıklı heparin He profilaksinin etkili ve güvenli olduğu gösterilmiştir. Venöz tromboemboiizm için rutin profilaksi uygulanması talidomid kullanan multipl miyelomalı hastalar dışında kanser tedavisi alan diğer hastalarda henüz standart değildir. Birçok çalışmada uzun dönem antikoagülasyonun kanser mortalitesi üzerine olumlu etkileri araştırılmaktadır.

Anahtar Kelimeler:

Kanser, tromboemboiizm.

Kanserin Tromboembolik Komplikasyonları ve Tedaviye Yönelik Yaklaşımlar

Venous thromboembolism is a common cause of mortality and morbidity in cancer patients. Risk factors for venous throm-boembolism include immobilization, surgery, hormonal treatments, chemotherapy and vascular injury due to venous catheters. Furthermore, most of the cancer cells release procoagulant substances which activate coagulation system directly or indirectly. İn case of high risk situations for venous thromboembolism such as hospitalization, surgery prophylactic use of low molecular vveight heparin is effective and safety. Unlike the patients with multiple myeloma receiving thalidomide, prophylaxis for venous thromboembolism has not been accepted as a Standard for patients receiving chemotherapy. Favorable effects of anticoagulati-on on cancer mortality are stili under investigation.

Keywords:

Cancer, thromboembolism.,

PDF

___

Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors and trends for venous thrombo- embolism among hospitalized cancer patients. Cancer 2007;110:2339-46.
Blom JW, Doggen CJ, Osanto S, Ftoserıtaal FR. Malignancies, protrombotic mutations, and the risk o f venous thrombosis. JAMA 2005;293:715-22.
Casiato DA. Hematologic complications. İn: Casiato DA, Territo MA (eds). Manual of Clinical Oncotogy. 5th ed. Philadelphia: Lippincott VVilliams & VVilkins, 2004:651-3.
Khorana AA, Francis C\N, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusion, thrombosis, and morta- lity in hospitalized patients with cancer. Arch Intern Med 2008;168:2377-81.
Geerts W, Pineo G, Heit JA, et al. Prevention of venous thromboembolism, the seventh ACCP conference on antith- rombotic and thrombolytic therapy. Chest2004;126:338-400.
Şamama M, Cohen A, Darmon JY, et al. A comparison of endoxaparin with placebo for prevention of venous throm boembolism in acutely ili medical patients. N Engl J Med 1999;341:739-800.
Leizorovicz A, Cohen AT, TurpieAG, et al; PREVENT medi cal thromboprophylaxis study group. A randomized, place- bo-controlled trial of deltaparin for the prevention of venous thromboembolism in acutely ili medical patients. Circulation 2004;110:874-9.
Cohen A, Davidson B, Gallus A, et al. ARTEMIS investiga- tors. Efficacy and safety of fondaparinux fort the prevention of venous thromboembolsim in older acute medical patients randomized placebo controlled trial. BMJ 2006;332:335-29.
ENOXACAN Study Group. Efficacy and safety of enoxapa- rin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment. B rJS urg 1997;84:1099-103.
Bergqvist D, Angelli G, Cohen AT. Duration of prophylaxis agaist venous thromboembolism with enoxaparin after sur gery for cancer. N Engl J Med 2002;346:975-80.
Agnelli G, Bergçvist D, Cohen AT, Gallus /4S, Gent M. PEGASUS investigators. Randomized clinical trial of posto- perative fondaparinux versus perioperative deltaparin for prevention of venous thromboembolism in high-risk abdo- minal surgery. Br J Surg 2005;92;10:1212-20.
Levine M, Hirsh J, Gent M, et al. Double-blind randomized trial of a very low dose warfarin for prevention of thromboem- bolism in stage IV breast cancer. Lancet 1994;343:886-9.
Haas SK. Prevention of venous thromboembolism with low- molecular weight heparin in patients metastatic breast or lung cancer: Results of TOPIC studies. J Thromb Haemost 2008:(Suppl 1);3.
Couban S, Goodyear M, Burnell M, et al. Randomized pla- cebo controlled study of low-dose warfarin fort the preventi on of Central venous catheter-associated thrombosis in pati ents with cancer. J Clin Oncol 2005; 23:4063-2.
Karthaus M, Kretzschmar A, Kröning H, et al. Deltaparin for prevention of catheter-related complications in cancer pati ents with Central venous catheters: Final results of a doub le-blind, placebo-controlled phase III trial. Ann Oncol 2006;17:289-96.
Prandoni P, Lensing AW, Piccoli A, et al. Recurrent venous thromboembolism and bleeding complications during anti- coagulant treatment for patients with cancer and venous thrombosis. Blood 2002;100:3484-8.
Hutten BA, Prins MH, Gent M. Incidence of recurrent throm- boembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved International normalized ratio: A retrospective analysis. J Clin Oncol 2000;18:3078-83.
Yildirim Y, Ozyilkan O, Akçalı Z, Basturk B. Drug interaction between capecitabine and warfarin: A case report and revi- ew of the literatüre. Int J Clin Oncol 2006;44:80-2.
Lee AY, Levine MN, Baker Rl, et al. Low-molecular weigth heparin versus a coumarin for the prevention of recurrent venous thromboembolism for patients with cancer. N Engl J Med 2003;349:146-53.
Meyer G, Marjanovic Z, Valcke J,et al. Comparison of low molecular vveight heparin and warfarin for the secondary prevention of venous thromboembolism for patients with cancer. Arch Intern Med 2002;162:1729-35.
Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular vveight heparin, therapy with deltaparin and survival in advanced cancer. The fragmin advanced malignancy outco- me study (FAMOUS). J Clin Oncol 2004;22:1944-8.
Kearon C, Kahn SR, Angelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombolitic therapy for venous thrombo- embolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest 2008;133:454-545.